Omalizumab, an anti-IgE monoclonal antibody, is increasingly being used in diseases other than allergic asthma. We report on the successful long-term management of refractory chronic urticaria in 2 patients using low-dose omalizumab.

Manteinance of remission with low-dose omalizumab in long-lasting, refractory chronic urticaria.

ROMANO, Ciro Pasquale;GIUNTA, Riccardo;LUCIVERO, Giacomo
2010

Abstract

Omalizumab, an anti-IgE monoclonal antibody, is increasingly being used in diseases other than allergic asthma. We report on the successful long-term management of refractory chronic urticaria in 2 patients using low-dose omalizumab.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11591/228204
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 34
  • ???jsp.display-item.citation.isi??? 29
social impact